Frontiers in Pharmacology | Pharmacoepidemiology

Original Research

Published on 16 Apr 2025

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

in Pharmacoepidemiology

Yunlin Yang
Jinfeng Liu
Wei Wei

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510992

7,444 views
3 citations

Original Research

Published on 16 Apr 2025

Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology

in Pharmacoepidemiology

Hao Xie
Lin Jiang
Junya Peng
Haoyang Hu
Meifen Han
Bin Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564127

5,988 views
3 citations

Editorial

Published on 15 Apr 2025

Editorial: Emerging trends in real-world pharmacoepidemiology: 2023

in Pharmacoepidemiology

Mohammed S. Salahudeen
Tatiane Da Silva Dal Pizzol
Li-Ting Kao
Gregory M. Peterson

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1601477

2,479 views

Correction

Published on 07 Apr 2025

Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Fengqi Zhou
Haiou He
Jing Gao
Zhen Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586073

1,181 views

Original Research

Published on 04 Apr 2025

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia

in Pharmacoepidemiology

Gashaw Sisay Chanie
Wagaye Atalay
Tirsit Ketsela Zeleke
Zemenu Wube Bayleyegn
Yonas Sisay Aragie
Gizachew Kassahun Bizuneh
Mihret Melese
Rahel Belete Abebe

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1394458

2,731 views

Original Research

Published on 26 Mar 2025

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024

in Pharmacoepidemiology

Jiali Xia
Jing Zhang
Hongyu Zhu
Li Ding

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1565480

4,606 views
1 citation

Original Research

Published on 26 Mar 2025

Community pharmacists’ views towards implementing a patient self-administered screening tool designed to identify risk of medication-related problems

in Pharmacoepidemiology

Mohammed S. Salahudeen
Ahmed Samy Saadeldean
Gregory M. Peterson
Behailu Terefe Tesfaye
Colin M. Curtain

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531500

1,902 views

Original Research

Published on 20 Mar 2025

The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis

in Pharmacoepidemiology

Feng Zhao
Yulan Chen
Haina Liu
Lei Jin
Xin Feng
Bingbing Dai
Meng Chen
Qiao Wang
Yuxin Yao
Ruobing Liao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1499723

1,632 views
1 citation

Systematic Review

Published on 18 Mar 2025

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients

in Pharmacoepidemiology

Shuai Geng
Yulong Shen
Chen Zhang
Nan Wang
Xinyue Gao
Xinyu Luo
Ning Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1563566

2,659 views
1 citation

Original Research

Published on 12 Mar 2025

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

in Pharmacoepidemiology

Chang-Zhu He
Qin Qiu
Song-Jie Lu
Fu-Li Xue
Jun-Qiao Liu
Yu He

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1521358

9,890 views
7 citations

Original Research

Published on 12 Mar 2025

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

in Pharmacoepidemiology

Chengyu Zhu
Zhiwei Cui
Tingting Liu
Siyu Lou
Linmei Zhou
Junyou Chen
Ruizhen Zhao
Li Wang
Yingyong Ou
Fan Zou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531514

4,111 views
5 citations

Original Research

Published on 10 Mar 2025

Development of a core outcome set for pharmacological interventions in osteoporosis among patients with diabetes mellitus: an international consensus study protocol

in Pharmacoepidemiology

Chao Wei
Xiaobin Wang
Zubing Mei
Jing Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510968

2,709 views
2 citations

Original Research

Published on 10 Mar 2025

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database

in Pharmacoepidemiology

Xiting Tang
Chengliang Wang
Yanwei Li
Jing Tang
Guoping Zhang
Li Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1538881

3,436 views
2 citations

Review

Published on 10 Mar 2025

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

in Pharmacoepidemiology

Ralf J. Ludwig
Matthew Anson
Henner Zirpel
Diamant Thaci
Henning Olbrich
Katja Bieber
Khalaf Kridin
Astrid Dempfle
Philip Curman
Sizheng S. Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1516126

25,054 views
87 citations

Original Research

Published on 05 Mar 2025

Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database

in Pharmacoepidemiology

Shanshan Wu
Lina Huang
Jiajia Chen
Xiaochun Xie
Shaokai Huang
Xiaojie Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1525307

4,436 views
4 citations

Original Research

Published on 19 Feb 2025

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

in Pharmacoepidemiology

Yu-Ting Huang
Tzu-Ling Chen
Yun-Lin Huang
Ching-Hua Kuo
Yu-Fong Peng
Sung-Chun Tang
Jiann-Shing Jeng
Chih-Feng Huang
Shin-Yi Lin
Fang-Ju Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1505665

3,719 views
4 citations

Original Research

Published on 18 Feb 2025

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

in Pharmacoepidemiology

Fang Wu
Siliang Wang
Xihui Xu
Weihui Zhang
Jie Zhou
Runyan Niu
Wenting Cai
Yonggong Yang
Mengying Liu
Jinping Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1459067

4,122 views
1 citation

Original Research

Published on 17 Feb 2025

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

in Pharmacoepidemiology

Long He
Jinwei Li
Xiong Cheng
Li Luo
Yilan Huang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1509561

7,308 views
6 citations

Original Research

Published on 13 Feb 2025

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

in Pharmacoepidemiology

Peng Jia
Yusen Zhou
Yuan Gao
Shangyu Wang
Jiangliu Yin
Yixiang Lian
Quanyou Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524159

4,808 views
6 citations

Original Research

Published on 13 Feb 2025

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

in Pharmacoepidemiology

Fengqi Zhou
Haiou He
Jing Gao
Zhen Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1488469

2,826 views
1 citation

Original Research

Published on 11 Feb 2025

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

in Pharmacoepidemiology

Shiyi Wang
Xiaojian Wang
Jing Ding
Xudong Zhang
Hongmei Zhu
Yihong Fan
Changbo Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1436183

6,417 views
6 citations

Correction

Published on 07 Feb 2025

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

in Pharmacoepidemiology

Xi-Feng Wang
Lu-Ri Bao
Ta-La Hu
Rui-Feng Xu
Wu-Niri Gao
Jing-Yuan Wang
Jian-Rong Zhao
Zhen-Li Fu
Shu-Fang Wang
Yan Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1558930

2,045 views
2 citations

Original Research

Published on 29 Jan 2025

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

in Pharmacoepidemiology

Taehyun Yang
Juhee Ahn
Sungho Won
Sanghun Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498124

8,039 views
2 citations

Original Research

Published on 24 Jan 2025

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults

in Pharmacoepidemiology

Hao Li
Manxue Jiang
Xiaona Pan
Lingti Kong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524702

3,322 views
3 citations

601 articles

articles

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database

Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology

Editorial: Emerging trends in real-world pharmacoepidemiology: 2023

Corrigendum: Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024

Community pharmacists’ views towards implementing a patient self-administered screening tool designed to identify risk of medication-related problems

The interaction between a leflunomide-response methylation site (cg17330251) and variant (rs705379) on response to leflunomide in patients with rheumatoid arthritis

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system

Development of a core outcome set for pharmacological interventions in osteoporosis among patients with diabetes mellitus: an international consensus study protocol

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database

A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX

Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

Exploring the association between herbal medicine usage and drug-induced liver injury: insights from a nationwide population-based cohort study using SCCS in South Korea

Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults